Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.

@article{Hope2006DerivationOA,
  title={Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.},
  author={William W Hope and Peter A. Warn and Andrew Sharp and Susan Howard and Miki Kasai and Arnold Louie and Thomas J Walsh and George L. Drusano and David William Denning},
  journal={Antimicrobial agents and chemotherapy},
  year={2006},
  volume={50 11},
  pages={3680-8}
}
Drug exposure or pharmacodynamic breakpoints refer to a magnitude of drug exposure which separates a population into groups with high and low probabilities of attaining a desired outcome. We used a pharmacodynamic model of disseminated candidiasis to define an in vivo drug exposure breakpoint for flucytosine (5FC) against Candida albicans. The results were bridged to humans by using population pharmacokinetics and Monte Carlo simulation. An in vivo drug exposure breakpoint for 5FC was apparent… CONTINUE READING